ERGOMED PLC (2EM.DE) Fundamental Analysis & Valuation

FRA:2EM • GB00BN7ZCY67

11 EUR
-0.42 (-3.68%)
Last: Mar 31, 2023, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This 2EM.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to 2EM. 2EM was compared to 18 industry peers in the Life Sciences Tools & Services industry. 2EM has an excellent financial health rating, but there are some minor concerns on its profitability. 2EM shows excellent growth, but is valued quite expensive already. This makes 2EM very considerable for growth investing!


Dividend Valuation Growth Profitability Health

5

1. 2EM.DE Profitability Analysis

1.1 Basic Checks

  • 2EM had positive earnings in the past year.
  • 2EM had a positive operating cash flow in the past year.
2EM.DE Yearly Net Income VS EBIT VS OCF VS FCF2EM.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 5M -5M 10M 15M 20M

1.2 Ratios

  • 2EM has a better Return On Assets (11.58%) than 87.50% of its industry peers.
  • Looking at the Return On Equity, with a value of 17.68%, 2EM is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
  • 2EM has a better Return On Invested Capital (19.56%) than 100.00% of its industry peers.
Industry RankSector Rank
ROA 11.58%
ROE 17.68%
ROIC 19.56%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
2EM.DE Yearly ROA, ROE, ROIC2EM.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 10 -10 -20 -30

1.3 Margins

  • 2EM has a Profit Margin (10.31%) which is in line with its industry peers.
  • In the last couple of years the Profit Margin of 2EM has grown nicely.
  • With a Operating Margin value of 14.14%, 2EM perfoms like the industry average, outperforming 43.75% of the companies in the same industry.
  • In the last couple of years the Operating Margin of 2EM has grown nicely.
  • 2EM has a Gross Margin (40.72%) which is comparable to the rest of the industry.
  • 2EM's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 14.14%
PM (TTM) 10.31%
GM 40.72%
OM growth 3Y6.85%
OM growth 5YN/A
PM growth 3Y8.12%
PM growth 5YN/A
GM growth 3Y-2%
GM growth 5Y1.94%
2EM.DE Yearly Profit, Operating, Gross Margins2EM.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. 2EM.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 2EM is creating value.
  • 2EM has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, 2EM has an improved debt to assets ratio.
2EM.DE Yearly Shares Outstanding2EM.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
2EM.DE Yearly Total Debt VS Total Assets2EM.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 9.27 indicates that 2EM is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of 2EM (9.27) is better than 93.75% of its industry peers.
  • The Debt to FCF ratio of 2EM is 0.22, which is an excellent value as it means it would take 2EM, only 0.22 years of fcf income to pay off all of its debts.
  • 2EM has a better Debt to FCF ratio (0.22) than 100.00% of its industry peers.
  • 2EM has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • 2EM has a Debt to Equity ratio of 0.02. This is amongst the best in the industry. 2EM outperforms 93.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.22
Altman-Z 9.27
ROIC/WACC2.4
WACC8.16%
2EM.DE Yearly LT Debt VS Equity VS FCF2EM.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 1.50 indicates that 2EM should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.50, 2EM is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
  • A Quick Ratio of 1.50 indicates that 2EM should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.50, 2EM is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.5
Quick Ratio 1.5
2EM.DE Yearly Current Assets VS Current Liabilites2EM.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. 2EM.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 16.60% over the past year.
  • The Earnings Per Share has been growing by 36.63% on average over the past years. This is a very strong growth
  • The Revenue has grown by 22.50% in the past year. This is a very strong growth!
  • 2EM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.99% yearly.
EPS 1Y (TTM)16.6%
EPS 3Y36.63%
EPS 5YN/A
EPS Q2Q%23.7%
Revenue 1Y (TTM)22.5%
Revenue growth 3Y28.63%
Revenue growth 5Y24.99%
Sales Q2Q%20.48%

3.2 Future

  • 2EM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.47% yearly.
  • Based on estimates for the next years, 2EM will show a quite strong growth in Revenue. The Revenue will grow by 9.07% on average per year.
EPS Next Y15.11%
EPS Next 2Y14.68%
EPS Next 3Y14.17%
EPS Next 5Y11.47%
Revenue Next Year12.58%
Revenue Next 2Y11.87%
Revenue Next 3Y10.64%
Revenue Next 5Y9.07%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
2EM.DE Yearly Revenue VS Estimates2EM.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
2EM.DE Yearly EPS VS Estimates2EM.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.2 0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

3

4. 2EM.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • 2EM is valuated quite expensively with a Price/Earnings ratio of 33.33.
  • The rest of the industry has a similar Price/Earnings ratio as 2EM.
  • 2EM is valuated rather expensively when we compare the Price/Earnings ratio to 26.69, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 20.66, 2EM is valued on the expensive side.
  • 2EM's Price/Forward Earnings ratio is rather cheap when compared to the industry. 2EM is cheaper than 81.25% of the companies in the same industry.
  • 2EM is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 24.79, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 33.33
Fwd PE 20.66
2EM.DE Price Earnings VS Forward Price Earnings2EM.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 62.50% of the companies in the same industry are more expensive than 2EM, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, 2EM is valued a bit cheaper than the industry average as 68.75% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 37.79
EV/EBITDA 17.91
2EM.DE Per share data2EM.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 2EM does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as 2EM's earnings are expected to grow with 14.17% in the coming years.
PEG (NY)2.21
PEG (5Y)N/A
EPS Next 2Y14.68%
EPS Next 3Y14.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 2EM.DE Dividend Analysis

5.1 Amount

  • No dividends for 2EM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

2EM.DE Fundamentals: All Metrics, Ratios and Statistics

ERGOMED PLC

FRA:2EM (3/31/2023, 7:00:00 PM)

11

-0.42 (-3.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap558.54M
Revenue(TTM)145.26M
Net Income(TTM)14.98M
Analysts85
Price Target16.93 (53.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-27.08%
Min Revenue beat(2)-27.08%
Max Revenue beat(2)-27.08%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.96%
PT rev (3m)4.14%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.99%
Valuation
Industry RankSector Rank
PE 33.33
Fwd PE 20.66
P/S 3.36
P/FCF 37.79
P/OCF 32.91
P/B 5.77
P/tB 17.77
EV/EBITDA 17.91
EPS(TTM)0.33
EY3%
EPS(NY)0.53
Fwd EY4.84%
FCF(TTM)0.29
FCFY2.65%
OCF(TTM)0.33
OCFY3.04%
SpS3.27
BVpS1.91
TBVpS0.62
PEG (NY)2.21
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 11.58%
ROE 17.68%
ROCE N/A
ROIC 19.56%
ROICexc 24.8%
ROICexgc 125.41%
OM 14.14%
PM (TTM) 10.31%
GM 40.72%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)96.55%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-22.79%
ROICexc growth 5YN/A
OM growth 3Y6.85%
OM growth 5YN/A
PM growth 3Y8.12%
PM growth 5YN/A
GM growth 3Y-2%
GM growth 5Y1.94%
F-Score4
Asset Turnover1.12
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.22
Debt/EBITDA 0.11
Cap/Depr 32.82%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 86.32%
Current Ratio 1.5
Quick Ratio 1.5
Altman-Z 9.27
F-Score4
WACC8.16%
ROIC/WACC2.4
Cap/Depr(3y)24.14%
Cap/Depr(5y)32.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)134.11%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.6%
EPS 3Y36.63%
EPS 5YN/A
EPS Q2Q%23.7%
EPS Next Y15.11%
EPS Next 2Y14.68%
EPS Next 3Y14.17%
EPS Next 5Y11.47%
Revenue 1Y (TTM)22.5%
Revenue growth 3Y28.63%
Revenue growth 5Y24.99%
Sales Q2Q%20.48%
Revenue Next Year12.58%
Revenue Next 2Y11.87%
Revenue Next 3Y10.64%
Revenue Next 5Y9.07%
EBIT growth 1Y6.17%
EBIT growth 3Y37.44%
EBIT growth 5YN/A
EBIT Next Year38.65%
EBIT Next 3Y20.29%
EBIT Next 5Y17.22%
FCF growth 1Y-26.93%
FCF growth 3Y6.22%
FCF growth 5YN/A
OCF growth 1Y-20.52%
OCF growth 3Y8%
OCF growth 5Y255.91%

ERGOMED PLC / 2EM.DE FAQ

Can you provide the ChartMill fundamental rating for ERGOMED PLC?

ChartMill assigns a fundamental rating of 5 / 10 to 2EM.DE.


What is the valuation status for 2EM stock?

ChartMill assigns a valuation rating of 1 / 10 to ERGOMED PLC (2EM.DE). This can be considered as Overvalued.


Can you provide the profitability details for ERGOMED PLC?

ERGOMED PLC (2EM.DE) has a profitability rating of 4 / 10.


What is the financial health of ERGOMED PLC (2EM.DE) stock?

The financial health rating of ERGOMED PLC (2EM.DE) is 7 / 10.


Can you provide the expected EPS growth for 2EM stock?

The Earnings per Share (EPS) of ERGOMED PLC (2EM.DE) is expected to grow by 15.11% in the next year.